AR063469A1 - Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades - Google Patents
Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedadesInfo
- Publication number
- AR063469A1 AR063469A1 ARP070103140A ARP070103140A AR063469A1 AR 063469 A1 AR063469 A1 AR 063469A1 AR P070103140 A ARP070103140 A AR P070103140A AR P070103140 A ARP070103140 A AR P070103140A AR 063469 A1 AR063469 A1 AR 063469A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- solution
- pyrrol
- dihydroxy
- heptanoic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Formas polimorficas de un inhibidor de reductasa HMG-CoA (3R, 5R)-7-[2-(4-fluorufenil)-5- isopropil-3-fenil-4-[(4-hidroximetilfenilamino) carbonil]-pirrol-1-il]-3,5-dihidroxi-acido heptanoico, hemi sal de calcio. También comprende métodos para preparar estas formas polimorficas, formulaciones farmacéuticas que, contienen estas formas polimorficas y métodos para usar las formas polimorficas del inhibidor de reductasa HMG-CoA. Reivindicacion 1: Un polimorfo cristalino de ácido (3R,5R)-7- [2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetiIfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio, que llene picos de difraccion de polvo de rayos X de, aproximadamente, 5,43; 7,95; 9,61; 11,29; 11,92; 18,91; 19,25; 22,78 y 23,95 2theta°. Reivindicacion 26: Un método para realizar una forma polimorfa cristalina de un inhibidor de la reductasa HMG-CoA, el cual comprende: a) disolver ácido (3R, 5R)-7-[2-(4-fluofenil)-5-isopropil 3-fenil-4-[(4- hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio, en un solvente que comprende agua y acetato de etilo para formar una solucion; b) enfriar la solucion a menos de, aproximadamente, 30°C y c) eliminar el solvente de la solucion a los fines de recuperar un polimorfo cristalino de la Forma 1 de ácido (3R, 5R)-7-[2(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi- heptanoico sal hemi calcio. Reivindicacion 27: Un método para realizar una forma polimorfa cristalina de un inhibidor de la reductasa HMG-CoA, el cual comprende: a) disolver ácido (3R,5R)-7-12-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-iI]-3,5-dihidroxi- heptanoico sal hemi calcio, en un solvente que comprende agua y etanol para formar una solucion; b) enfriar la solucion a menos de, aproximadamente, 30°C y c) eliminar el solvente de la solucion a los fines de recuperar un polimorfo cristalino de la Forma 1 de ácido (3R,5R)-7-[2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio.28. Reivindicacion 28: Un método para realizar una forma polimorfa cristalina de un inhibidor de la reductasa HMG-CoA, el cual comprende: a) disolver ácido (3R,5R)-7-(2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio, en un solvente que comprende agua y acetato de nitrilo para formar una solucion; b) enfriar la solucion a menos de, aproximadamente, 30°C y c) eliminar el solvente de la solucion a los fines de recuperar un polimorfo cristalino de la Forma II de ácido (3R,5R)-7-[2-(4-fluofenil)-5- isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1 il]-3,5-dihidroxi-heptanoico sal hemi calcio. Reivindicacion 29: Un método para realizar una forma polimorfa cristalina de un inhibidor de la reductasa HMG-CoA, el cual comprende: a) disolver ácido (3R,5R)-7-[2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio, en agua para formar una solucion; b) enfriar la solucion a menos de, aproximadamente, 30°C y c) eliminar el solvente de la solucion a los fines de recuperar un polimorfo cristalino de la Forma III de ácido (3R,5R)-7-[2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio. Reivindicacion 30: Un método para realizar una forma polimorfa cristalina de un inhibidor de la reductasa HMG-CoA, el cual comprende: a) disolver ácido (3R,5R)-7-[2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]- pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio, en un solvente que comprende agua y acetona para formar una solucion; b) enfriar la solucion a menos de, aproximadamente, 30°C y c) eliminar el solvente de la solucion a los fines de recuperar un polimorfo cristalino de la Forma IV ácido (3R,5R)-7-[2-(4-fluofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3,5-dihidroxi-heptanoico sal hemi calcio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1629DE2006 | 2006-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063469A1 true AR063469A1 (es) | 2009-01-28 |
Family
ID=38957150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103140A AR063469A1 (es) | 2006-07-14 | 2007-07-13 | Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080153896A1 (es) |
EP (1) | EP2049102A4 (es) |
JP (1) | JP2009543773A (es) |
CN (1) | CN101494980A (es) |
AR (1) | AR063469A1 (es) |
AU (1) | AU2007274724B2 (es) |
BR (1) | BRPI0714361A2 (es) |
CL (1) | CL2007002044A1 (es) |
MX (1) | MX2009000439A (es) |
RU (1) | RU2009105089A (es) |
TW (1) | TW200811101A (es) |
WO (1) | WO2008010087A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2319843B1 (en) * | 2003-05-30 | 2013-04-03 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
KR102013157B1 (ko) * | 2015-03-31 | 2019-08-23 | 대원제약주식회사 | 결정형 및 이의 제조방법 |
KR102218320B1 (ko) * | 2019-07-12 | 2021-02-23 | 대원제약주식회사 | (3r,5r)-7-(2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-((4-히드록시메틸페닐아미노)카보닐)-피롤-1-일)-3,5-디히드록시 헵탄산 헤미칼슘염의 제조방법, 및 이에 사용되는 중간체의 제조방법 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3262977A (en) * | 1962-03-10 | 1966-07-26 | Chinoin Gyogyszer Es Vegyeszet | N-aralkyl-1, 1-diphenyl-propylamine derivatives |
US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US3937838A (en) * | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
US3868460A (en) * | 1967-02-06 | 1975-02-25 | Boehringer Sohn Ingelheim | Therapeutic compositions and method |
US3562257A (en) * | 1967-10-28 | 1971-02-09 | Tanabe Seiyaku Co | Benzothiazepine derivatives |
US3674836A (en) * | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US3934032A (en) * | 1969-02-21 | 1976-01-20 | Imperial Chemical Industries Limited | Alkanolamine derivatives for treating hypertension |
US3716583A (en) * | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
US3655663A (en) * | 1969-04-21 | 1972-04-11 | Burton K Wasson | 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles |
US3663570A (en) * | 1969-04-28 | 1972-05-16 | Sankyo Co | Coumarin derivatives |
US3576883A (en) * | 1969-06-30 | 1971-04-27 | Consolidation Coal Co | Alkylidenedithiobisphenols |
US4012444A (en) * | 1969-07-08 | 1977-03-15 | Allen & Hanburys Limited | 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof |
AT296986B (de) * | 1969-08-13 | 1972-03-10 | Merz & Co | Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen |
BE755071A (fr) * | 1969-09-17 | 1971-02-22 | Warner Lambert Pharmaceutical | Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone |
US3635979A (en) * | 1969-09-29 | 1972-01-18 | Pfizer | Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines |
US3879554A (en) * | 1970-03-20 | 1975-04-22 | Farmaceutici Italia | Use of 1,6-dimethyl-8-{62 -(5-bromonicotinoyloxymethyl)-10 {60 -methoxyergoline in treating cerebral and peripheral metabolic vascular disorders |
US4032648A (en) * | 1970-04-06 | 1977-06-28 | Science Union Et Cie | Method and compositions containing thiochroman compounds for treating cardiac rhythm disorders |
US3669968A (en) * | 1970-05-21 | 1972-06-13 | Pfizer | Trialkoxy quinazolines |
US3932645A (en) * | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid |
DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
BE795735A (fr) * | 1972-03-06 | 1973-06-18 | Cerm Cent Europ Rech Mauvernay | Nouvelles ethylenediamines substituees a activite cardiovasculaire |
GB1435139A (en) * | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
DE2322232A1 (de) * | 1973-05-03 | 1974-11-14 | Thomae Gmbh Dr K | Neue acylaminosaeureamide |
US4011258A (en) * | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
AT334385B (de) * | 1973-12-20 | 1976-01-10 | Chemie Linz Ag | Verfahren zur herstellung von neuen phenoxypropylaminderivaten und deren salzen |
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
GB1501632A (en) * | 1974-06-28 | 1978-02-22 | Cm Ind | Aromatic ketones having cardiovascular activity |
DE2635209C2 (de) * | 1975-08-15 | 1983-01-27 | Sandoz-Patent-GmbH, 7850 Lörrach | 4-(2-Benzoyloxy-3-tert.butylamino-propoxy)-2-methylindol, dessen (S)-Enantiomeres, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Heilmittel |
GB1555654A (en) * | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
US4154839A (en) * | 1975-11-05 | 1979-05-15 | Bayer Aktiengesellschaft | 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine |
FR2330383A1 (fr) * | 1975-11-06 | 1977-06-03 | Synthelabo | Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment |
HU172137B (hu) * | 1976-03-02 | 1978-06-28 | Gyogyszerkutato Intezet | Sposob poluchenija zamehhjonnykh proizvodnykh fenoksi-propanolamina |
DE2645710C2 (de) * | 1976-10-09 | 1985-06-27 | Merck Patent Gmbh, 6100 Darmstadt | Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung |
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
IT1094076B (it) * | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
SE429652B (sv) * | 1978-06-30 | 1983-09-19 | Haessle Ab | 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester |
JPS559058A (en) * | 1978-07-06 | 1980-01-22 | Dainippon Pharmaceut Co Ltd | 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative |
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4508729A (en) * | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
JPS56110665A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
AU543804B2 (en) * | 1980-10-31 | 1985-05-02 | Takeda Chemical Industries Ltd. | Amides having bicyclic substituents on nitrogen |
US4337201A (en) * | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4425355A (en) * | 1981-02-17 | 1984-01-10 | Warner-Lambert Company | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids |
ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
JPS57171968A (en) * | 1981-04-17 | 1982-10-22 | Kyowa Hakko Kogyo Co Ltd | 1,4-dihydropyridine derivative |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
JPS60222472A (ja) * | 1984-03-30 | 1985-11-07 | Kanebo Ltd | 新規なピペラジン誘導体および該化合物を有効成分とする医薬組成物 |
US4672068A (en) * | 1984-05-04 | 1987-06-09 | Fujirebio Kabushiki Kaisha | Antihypertensive 1,4-dihydropyridines having a conjugated ester |
GB8418424D0 (en) * | 1984-07-19 | 1984-08-22 | Scras | Inhibition of platelets aggregation |
NZ212895A (en) * | 1984-08-22 | 1988-07-28 | Glaxo Spa | 1,4-dihydropyridine derivatives and pharmaceutical compositions |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
WO1988007525A1 (en) * | 1987-03-27 | 1988-10-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 1,4-dihydropyridine enantiomers |
SG59988A1 (en) * | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
GB8907256D0 (en) * | 1989-03-31 | 1989-05-17 | Rech Et D Applic Scient Scras | New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors |
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
IL97219A (en) * | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them |
ZA914764B (en) * | 1990-06-22 | 1992-03-25 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
WO1995001338A1 (de) * | 1993-07-02 | 1995-01-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
JP3286745B2 (ja) * | 1993-09-10 | 2002-05-27 | 日清食品株式会社 | シクロヘキサンジウレア誘導体及びその製法 |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
KR0136986B1 (ko) * | 1993-12-31 | 1998-04-25 | 김준웅 | 신규 징코라이드 유도체와 이의 제조방법 |
US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
US20040029962A1 (en) * | 1997-12-12 | 2004-02-12 | Chih-Ming Chen | HMG-COA reductase inhibitor extended release formulation |
US6168986B1 (en) * | 1998-01-23 | 2001-01-02 | Micron Technology, Inc. | Method of making a sacrificial self-aligned interconnect structure |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
DE19858789A1 (de) * | 1998-12-18 | 2000-06-21 | Bayer Ag | Kombination von Cerivastatin und Fibraten |
US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
PL200923B1 (pl) * | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu |
US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
ES2284646T3 (es) * | 2001-02-22 | 2007-11-16 | Jagotec Ag | Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos. |
CA2456732C (en) * | 2001-08-07 | 2012-10-30 | Galephar M/F | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor |
US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
US7169094B2 (en) * | 2002-10-09 | 2007-01-30 | Corepole, Inc. | Circular fitness apparatus |
US20040102511A1 (en) * | 2002-11-21 | 2004-05-27 | Jitendra Sattigeri | Substituted pyrrole derivatives |
US7762935B2 (en) * | 2003-02-20 | 2010-07-27 | Doble William C | Exercise apparatus resistance unit |
EP2319843B1 (en) * | 2003-05-30 | 2013-04-03 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
SE527189C2 (sv) * | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel |
US6884226B2 (en) * | 2003-07-02 | 2005-04-26 | Fred Pereira | Crib patting device |
WO2007032833A1 (en) * | 2005-08-15 | 2007-03-22 | Wyeth | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
-
2007
- 2007-07-13 BR BRPI0714361-3A patent/BRPI0714361A2/pt not_active IP Right Cessation
- 2007-07-13 US US11/777,503 patent/US20080153896A1/en not_active Abandoned
- 2007-07-13 EP EP07804921A patent/EP2049102A4/en not_active Withdrawn
- 2007-07-13 TW TW096125647A patent/TW200811101A/zh unknown
- 2007-07-13 AU AU2007274724A patent/AU2007274724B2/en not_active Ceased
- 2007-07-13 CL CL200702044A patent/CL2007002044A1/es unknown
- 2007-07-13 JP JP2009519002A patent/JP2009543773A/ja active Pending
- 2007-07-13 MX MX2009000439A patent/MX2009000439A/es not_active Application Discontinuation
- 2007-07-13 WO PCT/IB2007/002647 patent/WO2008010087A2/en active Application Filing
- 2007-07-13 RU RU2009105089/04A patent/RU2009105089A/ru not_active Application Discontinuation
- 2007-07-13 AR ARP070103140A patent/AR063469A1/es not_active Application Discontinuation
- 2007-07-13 CN CNA2007800268329A patent/CN101494980A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2049102A2 (en) | 2009-04-22 |
TW200811101A (en) | 2008-03-01 |
WO2008010087A2 (en) | 2008-01-24 |
CN101494980A (zh) | 2009-07-29 |
AU2007274724A1 (en) | 2008-01-24 |
BRPI0714361A2 (pt) | 2013-03-26 |
EP2049102A4 (en) | 2010-12-22 |
US20080153896A1 (en) | 2008-06-26 |
MX2009000439A (es) | 2009-02-04 |
RU2009105089A (ru) | 2010-08-27 |
CL2007002044A1 (es) | 2008-06-13 |
JP2009543773A (ja) | 2009-12-10 |
WO2008010087A3 (en) | 2009-04-23 |
AU2007274724B2 (en) | 2012-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
BRPI0612475B8 (pt) | métodos para a preparação de um composto | |
TW200728307A (en) | Novel spirochromanone derivatives | |
MY174452A (en) | Substituted piperidines that increase p53 activity and the uses thereof | |
MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
MX2009003739A (es) | Derivados de hidrobenzamida como inhibidores de hsp90. | |
HRP20141120T1 (hr) | Furazanobenzimidazoli kao predlijekovi za lijeäśenje neoplastiäśnih ili autoimunih bolesti | |
HRP20160540T1 (hr) | Sol i solvati jednog derivata tetrahidroizokinolina | |
UA99447C2 (ru) | Способ получения силденафила | |
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
WO2005002293A3 (en) | Cox-2-targeted imaging agents | |
AR063469A1 (es) | Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades | |
WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases | |
TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
ECSP056193A (es) | Derivados sustituidos del pirrol | |
MX2009010302A (es) | Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion. | |
WO2008003155A3 (en) | Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses | |
WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
EA200600605A1 (ru) | Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств | |
AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
EA199900057A1 (ru) | Ингибиторы матриксных металлопротеиназ | |
WO2007032010A3 (en) | Use of tellurium compounds for protection from ultra-violet radiation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |